Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005150 | 1.00 | DPP3 (0.53) | DPP3CAPN1CTSBOPRM1CCKBR | |
| SCHEMBL1369614 | 1.00 | DPP3 (0.53) | DPP3CAPN1CTSBOPRM1CCKBR | |
| SCHEMBL29565313 | 0.86 | DPP3 (0.58) | DPP3CAPN1CTSBOPRM1CCKBR | |
| SCHEMBL30052964 | 0.85 | DPP3 (0.69) | DPP3CAPN1CTSBDPP4 | |
| SCHEMBL19443228 | 0.82 | CAPN1 (0.59) | DPP3CAPN1CTSBOPRM1DPP4 | |
| SCHEMBL31396846 | 0.80 | DPP3 (0.56) | DPP3CAPN1CTSB | |
| SCHEMBL31091345 | 0.80 | DPP3 (0.57) | DPP3OPRM1 | |
| SCHEMBL29498112 | 0.80 | DPP4 (0.65) | DPP3DPP4 | |
| SCHEMBL31127569 | 0.79 | NTSR2 (0.54) | DPP3DPP4CXCR4 | |
| SCHEMBL12890870 | 0.79 | CXCR4 (0.54) | OPRM1CCKBRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | DPP3 370/4885CAPN1 2308/4885CTSB 160/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | DPP3 370/4885CAPN1 2308/4885CTSB 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.